Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-Week, Double-Blind, Randomized, Controlled Trial

Diabetes Care - United States
doi 10.2337/diacare.27.6.1335
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Diabetes Association

Related search

Dose-Dependent Effects of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized, Double-Blind, Placebo-Controlled Trial

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2010English

Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes: A Randomized Controlled Trial

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2009English

Effect of Adding Insulin Degludec to Treatment in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Liraglutide: A Double-Blind Randomized Controlled Trial (BEGIN: ADD TO GLP-1 Study)

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Randomized, Double-Blind, Placebo-Controlled Trial of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Asian Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin With or Without a Sulfonylurea (GetGoal-L-Asia)

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2012English

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients With Type 2 Diabetes: A Randomized Controlled Trial

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2018English

Propolis Supplementation Improves Glycemic and Antioxidant Status in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study

Complementary Therapies in Medicine
Alternative MedicineManual TherapySpecialized NursingAdvancedComplementary
2019English

The Glucagon-Like Peptide-1 Analog Liraglutide Suppresses Ghrelin and Controls Diabetes in a Patient With Prader-Willi Syndrome

Endocrine Journal
EndocrinologyMetabolismDiabetes
2012English

Pdb20 - Persistence to Liraglutide Therapy Is Associated With Better Glycemic and Weight Control in Patients With Type 2 Diabetes

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Safety, Tolerability and Sustained Weight Loss Over 2 Years With the Once-Daily Human GLP-1 Analog, Liraglutide

International Journal of Obesity
NutritionEndocrinologyDieteticsMedicineMetabolismDiabetes
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy